secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001140361-24-036281
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q1 net income $57.5M, cash $5.7B; pipeline advances in MG, DM, NIU
--------------------------------------------------------------------------

- Net income of $57.5M vs net loss of $327.8M YoY; diluted EPS $0.12 vs ($0.38).
- Total revenue $55.1M, product revenue $18.4M from VTAMA; license/milestone $36.8M.
- Cash, cash equivalents and restricted cash $5.7B at June 30, 2024, reflecting $648M share repurchase.
- Immunovant completed enrollment in batoclimab pivotal MG trial; brepocitinib Phase 3 VALOR in DM completed enrollment.
- Priovant to initiate Phase 3 for brepocitinib in NIU; VTAMA PDUFA action expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124036281/0001140361-24-036281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124036281/ef20033756_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer